News

Most Recent Press Releases

07/14/2010

Plexxikon's Novel Agent Significantly Inhibits Activation of Key CNS Cells Associated With Alzheimer's Disease

06/06/2010

PLX4032 Phase 1 Extension Data in Colorectal Cancer Reported

04/20/2010

Plexxikon's PLX3397 Preclinical Data Demonstrate Potential of Novel, "First-in-Class" Cancer Drug

04/19/2010

Plexxikon Co-Founder Joseph Schlessinger, Ph.D., Awarded 2010 Pezcoller Foundation-AACR International Award for Cancer Research

01/08/2010

Plexxikon Announces First Patient Dosed in Phase 3 Trial

Additional Press Releases

PR Contacts

Susan Kinkead
Kinkead Communications
415.751.3611
susan@kinkeadcomm.com

Jennifer Cook Williams
Cook Williams Communications
360.668.3701
jennifer@cwcomm.org